Center of Experimental Orthopaedics, Saarland University, Homburg/Saar, Germany; Department of Orthopaedic Surgery, Saarland University Medical Center, Homburg/Saar, Germany.
Osteoarthritis Cartilage. 2013 Apr;21(4):614-24. doi: 10.1016/j.joca.2013.01.008. Epub 2013 Jan 24.
The 1-34 amino acid segment of the parathyroid hormone (PTH [1-34]) mediates anabolic effects in chondrocytes and osteocytes. The aim of this study was to investigate whether systemic application of PTH [1-34] improves the repair of non-osteoarthritic, focal osteochondral defects in vivo.
Standardized cylindrical osteochondral defects were bilaterally created in the femoral trochlea of rabbits (n = 8). Daily subcutaneous injections of 10 μg PTH [1-34]/kg were given to the treatment group (n = 4) for 6 weeks, controls (n = 4) received saline. Articular cartilage repair was evaluated by macroscopic, biochemical, histological and immunohistochemical analyses. Reconstitution of the subchondral bone was assessed by micro-computed tomography. Effects of PTH [1-34] on synovial membrane, apoptosis, and expression of the PTH receptor (PTH1R) were determined.
Systemic PTH [1-34] increased PTH1R expression on both, chondrocytes and osteocytes within the repair tissue. PTH [1-34] ameliorated the macro- and microscopic aspect of the cartilaginous repair tissue. It also enhanced the thickness of the subchondral bone plate and the microarchitecture of the subarticular spongiosa within the defects. No significant correlations were established between these coexistent processes. Apoptotic levels, synovial membrane, biochemical composition of the repair tissue, and type-I/II collagen immunoreactivity remained unaffected.
PTH [1-34] emerges as a promising agent in the treatment of focal osteochondral defects as its systemic administration simultaneously stimulates articular cartilage and subchondral bone repair. Importantly, both time-dependent mechanisms of repair did not correlate significantly at this early time point and need to be followed over prolonged observation periods.
甲状旁腺激素(PTH[1-34])的 1-34 个氨基酸片段在软骨细胞和破骨细胞中介导合成代谢作用。本研究旨在探讨全身应用 PTH[1-34]是否能改善体内非骨关节炎、局灶性骨软骨缺损的修复。
在兔股骨滑车双侧建立标准化的圆柱状骨软骨缺损(n=8)。治疗组(n=4)每天皮下注射 10μg PTH[1-34]/kg,持续 6 周,对照组(n=4)给予生理盐水。通过大体、生化、组织学和免疫组织化学分析评估关节软骨修复情况。通过微计算机断层扫描评估软骨下骨的重建情况。测定 PTH[1-34]对滑膜、细胞凋亡和甲状旁腺激素受体(PTH1R)表达的影响。
全身应用 PTH[1-34]增加了修复组织中软骨细胞和破骨细胞上的 PTH1R 表达。PTH[1-34]改善了软骨修复组织的宏观和微观外观。它还增强了缺陷内软骨下骨板的厚度和亚关节松质骨的微结构。这些共存过程之间没有建立显著的相关性。凋亡水平、滑膜、修复组织的生化组成和 I/II 型胶原免疫反应性没有受到影响。
PTH[1-34]作为一种有前途的治疗局灶性骨软骨缺损的药物,其全身给药可同时刺激关节软骨和软骨下骨修复。重要的是,这两种修复机制在这个早期时间点没有显著相关性,需要在延长的观察期内进行跟踪。